PAŘENICA, Jiří, Petr NĚMEC, Josef TOMANDL, Jiří ONDRÁŠEK, Monika PÁVKOVÁ GOLDBERGOVÁ, Martin TŘETINA, Jiří JARKOVSKÝ, Simona LITTNEROVÁ, Martin POLOCZEK, Petr POKORNÝ, Jindřich ŠPINAR, Zdeňka ČERMÁKOVÁ, Roman MIKLÍK, Petr MALÍK, Ondřej PEŠ, Jolana LIPKOVÁ, Marie TOMANDLOVÁ and Petr KALA. Prognostic Utility of Biomarkers in Predicting of One- Year Outcomes in Patients with Aortic Stenosis Treated with Transcatheter or Surgical Aortic Valve Implantation. PloS ONE. 2012, vol. 7, No 12, p. e48851, 11 pp. ISSN 1932-6203. doi:10.1371/journal.pone.0048851.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Prognostic Utility of Biomarkers in Predicting of One- Year Outcomes in Patients with Aortic Stenosis Treated with Transcatheter or Surgical Aortic Valve Implantation
Authors PAŘENICA, Jiří (203 Czech Republic, belonging to the institution), Petr NĚMEC (203 Czech Republic), Josef TOMANDL (203 Czech Republic, belonging to the institution), Jiří ONDRÁŠEK (203 Czech Republic), Monika PÁVKOVÁ GOLDBERGOVÁ (203 Czech Republic, belonging to the institution), Martin TŘETINA (203 Czech Republic), Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution), Simona LITTNEROVÁ (203 Czech Republic, belonging to the institution), Martin POLOCZEK (203 Czech Republic, belonging to the institution), Petr POKORNÝ (203 Czech Republic), Jindřich ŠPINAR (203 Czech Republic, belonging to the institution), Zdeňka ČERMÁKOVÁ (203 Czech Republic, belonging to the institution), Roman MIKLÍK (203 Czech Republic), Petr MALÍK (203 Czech Republic), Ondřej PEŠ (203 Czech Republic, belonging to the institution), Jolana LIPKOVÁ (203 Czech Republic, belonging to the institution), Marie TOMANDLOVÁ (203 Czech Republic, belonging to the institution) and Petr KALA (203 Czech Republic, guarantor, belonging to the institution).
Edition PloS ONE, 2012, 1932-6203.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30201 Cardiac and Cardiovascular systems
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 3.730
RIV identification code RIV/00216224:14110/12:00062521
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1371/journal.pone.0048851
UT WoS 000312386800004
Keywords in English Aortic Stenosis; Transcatheter; Aortic Valve Implantation; Outcome
Changed by Changed by: Ing. Mgr. Věra Pospíšilíková, učo 9005. Changed: 22/4/2013 18:46.
Abstract
Objectives: The aim of the work was to find biomarkers identifying patients at high risk of adverse clinical outcomes after TAVI and SAVR in addition to currently used predictive model (EuroSCORE). Methods: The multi-biomarker sub-study included 42 consecutive high-risk patients (average age 82.0 years; logistic EuroSCORE 21.0%) allocated to TAVI transfemoral and transapical using the Edwards-Sapien valve (n = 29), or SAVR with the Edwards Perimount bioprosthesis (n = 13). Standardized endpoints were prospectively followed during the 12-month follow-up. Results: The clinical outcomes after both TAVI and SAVR were comparable. Malondialdehyde served as the best predictor of a combined endpoint at 1 year with AUC (ROC analysis) = 0.872 for TAVI group, resp. 0.765 (p,0.05) for both TAVI and SAVR groups. Increased levels of MDA, matrix metalloproteinase 2, tissue inhibitor of metalloproteinase (TIMP1), ferritin-reducing ability of plasma, homocysteine, cysteine and 8-hydroxy-2-deoxyguanosine were all predictors of the occurrence of combined safety endpoints at 30 days (AUC 0.750–0.948; p,0.05 for all). The addition of MDA to a currently used clinical model (EuroSCORE) significantly improved prediction of a combined safety endpoint at 30 days and a combined endpoint (0–365 days) by the net reclassification improvement (NRI) and the integrated discrimination improvement (IDI) (p,0.05). Cystatin C, glutathione, cysteinylglycine, asymmetric dimethylarginine, nitrite/nitrate and MMP9 did not prove to be significant. Total of 14.3% died during 1-year follow-up. Conclusion: We identified malondialdehyde, a marker of oxidative stress, as the most promising predictor of adverse outcomes during the 30-day and 1-year follow-up in high-risk patients with symptomatic, severe aortic stenosis treated with TAVI. The development of a clinical ‘‘TAVIscore’’ would be highly appreciated. Such dedicated scoring system would enable further testing of adjunctive value of various biomarkers.
Links
MUNI/A/0831/2011, internal MU codeName: Příspěvek chemických a biochemických metodik ke studiu molekulární podstaty vybraných patologických stavů a onemocnění
Investor: Masaryk University, Grant Agency of Masaryk University, Category A
PrintDisplayed: 15/4/2021 01:58